Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
5 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The exclusive private-market partnership will make Takeda’s QDENGA available for pediatric and adult vaccination, with launch expected in H1 2027Dr. Reddy’s Laboratories and Takeda Pharmaceutical Company have entered into an exclusive distribution agreement to promote and distribute Takeda’s QDENGA…
Takeda and Dr. Reddy’s Labs (DRL) plan to pair to promote and distribute Qdenga, a dengue prevention vaccine, targeted at the private market for pediatric use. Launch is expected in the first half of 2027.
* Shares of India's Dr. Reddy's rise as much as 2.76% to 1,207.50 rupees * REDY's signed an agreement with Japanese drugmaker Takeda Pharmaceutical to promote and distribute the Qdenga dengue vaccine in India * India's drug regulator approved Qdenga for use in both children and adults, making it the first dengue vaccin
(Adds details paragraph 2 onwards) Sept 18 (Reuters) — Dr Reddy's Laboratories said on Friday it had signed an agreement with Japanese drugmaker Takeda Pharmaceutical to promote and distribute the Qdenga dengue vaccine in India. The deal comes months after India's drug regulator approved Qdenga for use in both children
Dr Reddy's Laboratories said it signed an agreement with Takeda Pharmaceutical to promote and distribute Qdenga in India, months after India’s regulator approved Qdenga for use in both children and adults.